Search

This report summarizes the presentations and discussions in the first Asian Clinical Trials Network for Cancers (ATLAS) international symposium that was held on 24 April 2022, in Bangkok, Thailand, and hosted by the National Cancer Center Hospital (NCCH), co-hosted by the Pharmaceuticals and Medical Devices Agency (PMDA), Clinical Research Malaysia (CRM) and the Thai Society of Clinical Oncology (TSCO), and supported by Embassy of Japan in Thailand. Since 2020, the NCCH has conducted the ATLAS project to enhance research environments and infrastructures to facilitate international clinical research and cancer genomic medicine in the Asian region. The purpose of the symposium was to discuss what we can achieve under the ATLAS project, to share the latest topics and common issues in cancer research and to facilitate mutual understanding. Invitees included stakeholders from academic institutions, mainly at ATLAS collaborative sites, as well as Asian regulatory authorities. The invited speakers discussed ongoing collaborative research, regulatory perspectives to improve new drug access in Asia, the status of phase I trials in Asia, the introduction of research activities at the National Cancer Center (NCC) and the implementation of genomic medicine. As the next steps after this symposium, the ATLAS project will foster increased cooperation between investigators, regulatory authorities and other stakeholders relevant to cancer research, and establish a sustainable pan-Asian cancer research group to increase the number of clinical trials and deliver novel drugs to patients with cancer in Asia.

Historically, the majority of oncology clinical trials are conducted in Western Europe and North America. Globalization of drug development has resulted in sponsors shifting their focus to the Asia-Pacific region. In Malaysia, implementation of various government policies to promote clinical trials has been initiated over a decade ago and includes the establishment of Clinical Research Malaysia, which functions as a facilitator and enabler of industry-sponsored clinical trials on a nationwide basis. Although oncology clinical trials in Malaysia have seen promising growth, there are still only a limited number of early phase oncology studies being conducted. Hence, the Phase 1 Realization Project was initiated to develop Malaysia's early phase clinical trial capabilities. In addition, the adaptation of good practices from other countries contribute to the effective implementation of existing initiatives to drive progress in the development of early phase drug development set up in Malaysia. Furthermore, holistic approaches with emphasis in training and education, infrastructure capacities, strategic alliances, reinforcement of upstream activities in the value chain of drug development, enhanced patient advocacy, coupled with continued commitment from policy makers are imperative in nurturing a resilient clinical research ecosystem in Malaysia.

Historically, the majority of oncology clinical trials are conducted in Western Europe and North America. Globalization of drug development has resulted in sponsors shifting their focus to the Asia-Pacific region. In Malaysia, implementation of various government policies to promote clinical trials has been initiated over a decade ago and includes the establishment of Clinical Research Malaysia, which functions as a facilitator and enabler of industry-sponsored clinical trials on a nationwide basis. Although oncology clinical trials in Malaysia have seen promising growth, there are still only a limited number of early phase oncology studies being conducted. Hence, the Phase 1 Realization Project was initiated to develop Malaysia's early phase clinical trial capabilities. In addition, the adaptation of good practices from other countries contribute to the effective implementation of existing initiatives to drive progress in the development of early phase drug development set up in Malaysia. Furthermore, holistic approaches with emphasis in training and education, infrastructure capacities, strategic alliances, reinforcement of upstream activities in the value chain of drug development, enhanced patient advocacy, coupled with continued commitment from policy makers are imperative in nurturing a resilient clinical research ecosystem in Malaysia.

The Malaysian government is committed to improve clinical research infrastructure. More than 7 years after Clinical Research Malaysia (CRM) formation, we have more than 150 Clinical Research Sites and 850 clinical research investigators registered for multiple discipline of medicine. The top 10 common cancers in Malaysia includes Breast, Colorectal, Lung, Lymphoma, Nasopharynx, Leukemia, Prostate, Cervical, Liver and Ovarian cancer. Every tear Malaysia conducted 40 new Oncology clinical research sponsored by multinational companies. Majority are in Clinical Trial Phase 2 and 3. In 2017, CRM launch Phase 1 Realisation Program to produce First in Human (FIH) Phase 1 centers. 2 years later the first FIH center was accredited for Phase FIH Clinical Research. The Oncology disease prevalence is indifferent with the developed nation couple with multiple variety of population, Malaysia is ideal for clinical research destination. In addition, the conduct of Clinical Research is governed by Good Clinical Practice with ISO 9001:2015 accredited Standard Operating Procedure. The conducive environments mean clinical research are delivered according to the speed, reliability and quality. The recent reported recruitment rate at 83% has prepared the clinical research sites in facing COVID-19 pandemic where we will describe the recovery of clinical research recruitment is accelerated. The speaker will share data on how the research environment in Malaysia transformed creating conducive environment for oncology clinical research. Consequently, achieving 2 out of 3 National Key Economic Area Key Performance Index, ahead by almost 3 years with new jobs created and more number industry sponsored research conducted in the country.